Insilico Medicine Secures Revolving Loan Facility with HSBC to Boost Drug Discovery Pipeline
China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving...
Insilico Medicine
Insilico Medicine and Seto Biopartner to Leverage AI in Synthetic Biology and Drug Discovery
Insilico Medicine has announced a strategic partnership with Seto Bio (SHE: 300583) to harness cutting-edge...
Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study
China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its...
Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...
Insilico Medicine’s ISM6331 Earns FDA Orphan Drug Designation for Mesothelioma Treatment
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
AI-Powered Biotech Insilico Medicine Initiates Phase I Clinical Trial for Inflammatory Bowel Disease Drug
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors
China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing...
Insilico Medicine Partners with invoX Pharma to Boost AI-Driven Drug Discovery
China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with...
AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics
Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into...
Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with...
Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD
Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of...
Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement...
Insilico Medicine’s AI-Discovered Drug INS018_055 Reaches Phase II Clinical Trial Milestone
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has announced that its lead pipeline candidate,...
Insilico Medicine Partners with ShanghaiTech University for Tumor Drug R&D Advancement
China-based AI-powered drug discovery firm Insilico Medicine has struck a partnership with ShanghaiTech University’s iHuman...
Insilico Medicine’s COVID-19 Drug ISM3312 Enters Clinical Trials
China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19...
Insilico Medicine Opens AI Biotech Research Center in Abu Dhabi
China-based AI-powered drug discovery firm Insilico Medicine has revealed the opening of an AI-powered biotechnology...
Insilico Medicine Partners with Sanofi for AI-Driven Drug Discovery
Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company based in Hong Kong, has announced...
Insilico Medicine Closes USD95m Series D Financing to Advance AI Drug Discovery
Insilico Medicine, a Hong Kong-based artificial intelligence (AI)-driven drug discovery company, announced the closure of...
Insilico Medicine Identifies Novel ALS Therapeutic Targets via AI Platform PandaOmics
China-based Insilico Medicine announced the identification of multiple novel therapeutic targets for amyotrophic lateral sclerosis...